Methylation at two key differentially methylated regions (DMRs) of the MGMT promoter, DMR1 and DMR2, has been identified as contributing factors of MGMT silencing in GBM patients [133, 134], which accounts for approximately 45% of patients [135]. This evidence concerns the gene MGMT and glioblastoma.